Pulse Biosciences, Inc. announced a new publication in the Journal Thyroid showcasing the effectiveness of ablation of benign thyroid nodules using Nanosecond Pulsed Field Ablation technology.
The study conducted in Naples, Italy, demonstrated up to 93% reduction in size of fully treated nodules at 1 year, with symptom relief as early as 2 weeks.
The technology offers advantages over traditional methods like thyroidectomy or thermal ablation with rapid symptom reduction and minimal side effects.
Benefits of nsPFA
nsPFA offers a safe and effective option for treating benign thyroid nodules, with up to 93% reduction in nodule size and rapid symptom relief.
Advantages Over RFA
nsPFA preserves nerves and blood vessels, enabling treatment in sensitive areas with faster nodule volume reduction compared to Radiofrequency Ablation (RFA).
Clinical Feasibility Study Success
The First-In-Human study demonstrated the effectiveness of CellFX nsPFA technology in treating benign thyroid nodules with favorable safety outcomes.
- The study results indicate that CellFX nsPFA technology has the potential to revolutionize the treatment of benign thyroid nodules by providing a safer, faster, and more effective alternative to traditional approaches.
- The rapid reduction in nodule size, combined with the absence of adverse effects, highlights the significant impact nsPFA can have on improving patient outcomes and surgical procedures.
The publication of the First-In-Human data in the Journal Thyroid marks a significant milestone for Pulse Biosciences, reaffirming the potential of nsPFA technology to transform the treatment landscape for benign thyroid nodules.